H.C. Wainwright lowered the firm’s price target on Sanara MedTech (SMTI) to $36 from $54 and keeps a Buy rating on the shares following the Q3 report. The company plans to execute its commercial plan and improve operational efficiency to support sustainable revenue growth and improved profitability going forward, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMTI: